On October 8, the FDA approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation. For more information, read the FDA announcement and the Regeneron Pharmaceuticals press release.
On October 8, the FDA approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
For more information, read the FDA announcement and the Regeneron Pharmaceuticals press release.
Posted on 10/9/2025
